Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Rhea-AI Summary

Novavax (NVAX) has announced it will host a conference call on Thursday, February 27, 2025, at 8:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results and operational highlights. The company, which specializes in protein-based vaccines with its Matrix-M™ adjuvant technology, will provide participants with options to join the call either through automated registration or operator assistance.

GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows:

Conference call details:
Date:	February 27, 2025
Time:	8:30 a.m. U.S. ET
URL to register phone:	https://emportal.ink/3PsP11e
Dial-in number:	(800) 836-8184 (Domestic) or
	(+1) (646) 357-8785 (International)
Webcast:	ir.novavax.com/events

• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

Replay details:
Date:	Available starting at 11:30 a.m. U.S. ET, February 27, 2025, until 11:59 p.m. U.S. ET, March 6, 2025
Dial-in number:	(888) 660-6345 (Domestic) or
	(+1) (646) 517-4150 (International)
Passcode:	79349#
Webcast:	ir.novavax.com/events, until March 29, 2025

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights-on-february-27-2025-302381190.html

SOURCE Novavax, Inc.

FAQ

When will Novavax (NVAX) report Q4 and full year 2024 earnings?

Novavax will report its Q4 and full year 2024 financial results on Thursday, February 27, 2025, at 8:30 a.m. Eastern Time.

How can investors join the Novavax (NVAX) Q4 2024 earnings call?

Investors can join either through automated registration with their phone number for an automatic callback or by dialing in directly to be connected by an operator.

What will be discussed in Novavax's (NVAX) February 27 conference call?

The conference call will cover Novavax's fourth quarter and full year 2024 financial results and operational highlights.

What time should participants join the Novavax (NVAX) earnings call?

Participants are recommended to join at least 10 minutes prior to the scheduled webcast time of 8:30 a.m. ET.